A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Advanced Malignant Solid Tumors|Breast Neoplasms
Interventions: DRUG: HKI-272|DRUG: Paclitaxel
Sponsor: Puma Biotechnology, Inc.